Live Breaking News & Updates on Rare diseases

AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K

AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Cambridge , Cambridgeshire , Washington , United-states , Pascal-soriot , Adrian-kemp , European-union-withdrawal , Commission-file-number , Company-secretary , Nasdaq , Astrazeneca

Novo Nordisk: Stifel raises its target price

Novo Nordisk: Stifel raises its target price
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Roche-hemlibra , Novo-nordisk , Rare-diseases , Cercle-finance ,

A1AT Phenotyping Lags Behind, Contributes to Underrecognition of AATD

A1AT Phenotyping Lags Behind, Contributes to Underrecognition of AATD
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Americans , Rubinsteini-alpha , Zane-elfessi , Veterans-affairs , National-organization-of-rare-diseases , Jesse-brown-veterans-affairs-medical-center , University-of-chicago , National-organization-for-rare-disorders , National-organization , Rare-diseases

THE STRONG PERFORMANCE OF THE GROUP CONTINUES IN THE FIRST QUARTER OF 2024: REVENUE +10.2%, EBITDA +10.5%, ADJUSTED NET INCOME +5.6%

THE STRONG PERFORMANCE OF THE GROUP CONTINUES IN THE FIRST QUARTER OF 2024: REVENUE +10.2%, EBITDA +10.5%, ADJUSTED NET INCOME +5.6%
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Italy , Milan , Lombardia , Monza , Germany , France , United-kingdom , Turkey , China , Brunswick , Niedersachsen , United-states

Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50% - Takeda Pharmaceutical (NYSE:TAK)

Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50% - Takeda Pharmaceutical (NYSE:TAK)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Japan , Christophe-weber , Drug-association , Takeda-pharmaceutical-company-limited , Takeda-pharmaceutical-company , Plasmaderived-therapies , Rare-diseases , Chief-executive-christophe-weber , Launch-products , Core-operating-margin , Good-news-for-sleep-disorder-patients , Therapy-shows-promise-in-mid-stage